X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Pentec will receive the exclusive rights to distribute Altemia (docosahexaenoic acid ethyl ester), a proprietary oral formulation of emulsified docohexanoic acid, clinically evaluated to restore DHA levels and help reduce inflammation associated with SCD, in the United States.
Lead Product(s): DHA
Therapeutic Area: Hematology Product Name: Altemia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pentec Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 17, 2023
Details:
Aptamil (Iron) First Infant Milk Stage 1(This infant formula is appropriate for most infants and meets U.S. nutrient requirements, but it may not be suitable for infants born prematurely, or with a low birth weight.
Therapeutic Area: Hematology Product Name: Aptamil
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2022
Details:
The partnership will see Catalent use its proprietary OptiGel® DR technology to encapsulate OmeGo (docosahexaenoic acid), HBC’s unique fish oil derived from sustainable, traceable, and fresh Norwegian Atlantic salmon.
Lead Product(s): DHA,Icosapent Ethyl
Therapeutic Area: Immunology Product Name: OmeGo
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hofseth BioCare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 12, 2021
Details:
Université de Sherbrooke in Canada will test if LYSOVETA, Aker BioMarine’s new delivery platform based on LPC-bound EPA/DHA from krill, is more effective in increasing the concentration of DHA in the brain and improving cognition.
Lead Product(s): Icosapent Ethyl,DHA
Therapeutic Area: Neurology Product Name: Lysoveta
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aker BioMarine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 15, 2021
Details:
Comapny's first D-PUFA drug candidate in development, RT001, has shown robust safety in over 50 patient years of oral dosing, and we expect RT011 to have a similar safety profile.
Lead Product(s): DHA
Therapeutic Area: Ophthalmology Product Name: RT011
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
